Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Infections, Skin clinical trials.
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed blood cancer (such as leukemia, lymphoma, or myeloma) that has come back or stopped responding after at least 2 prior treatments
- Cancer cells must have the right protein markers (antigens) that the CAR-T cells can recognize
- Overall health status allows for the treatment (able to do light activities or better)
- Heart, kidney, and liver function adequate enough to safely receive the treatment
- Able to undergo leukapheresis (a procedure to collect immune cells from your blood) and willing to follow all study visits and rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
This study tests a new type of cell therapy that engineers your own immune cells to find and attack cancer cells that have either CD19 or CD20 markers. It is for people with B-cell lymphomas or leukemias that have come back or not responded to other treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
Hear when a new T Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.